Your browser doesn't support javascript.
loading
Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.
Chen, Lucia Y; Shah, Raakhee; Cwynarski, Kate; Lambert, Jonathan; McNamara, Christopher; Mohamedbhai, Sajir G; Virchis, Andres; Townsend, William; D'Sa, Shirley; Ardeshna, Kirit M.
Afiliación
  • Chen LY; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Shah R; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Cwynarski K; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Lambert J; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • McNamara C; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Mohamedbhai SG; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Virchis A; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Townsend W; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • D'Sa S; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Ardeshna KM; Lymphoma service, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Br J Haematol ; 184(3): 462-465, 2019 02.
Article en En | MEDLINE | ID: mdl-29363752

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / Rituximab / Anticuerpos Monoclonales Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / Rituximab / Anticuerpos Monoclonales Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2019 Tipo del documento: Article